MetaCap

Damora Therapeutics Inc. (DMRA)

NASDAQ: DMRAHealth CareBiotechnology: Pharmaceutical PreparationsUSD

23.22-1.08 (-4.44%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

DMRA stock chart

Technical analysis

Key statistics

All statistics
52-week range
15.76 – 38.33
Day range
23.13 – 24.51
Volume / Avg
643.38K / 584.28K
Beta
—

52-week range

$15.76$38.33

DMRA stock today

Damora Therapeutics (DMRA) closed at $23.22 on Nov 20, down 4.44% (-$1.08), versus the S&P 500's 3.70% decline. At this level, DMRA sits in the middle of its 52-week range of $15.76 to $38.33: 39.4% below the high, set on Dec 26, 2025 and 47.3% above the low. DMRA is up 0.9% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 38.5%.

At 13.6x trailing earnings, Damora Therapeutics trades above the peer-group median of 7.2x.

Summary generated from market data by MetaCap's automated system. Methodology

About Damora Therapeutics

Company profile

Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company's lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatment of acute myeloid leukemia.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Ms. Jennifer A. Jarrett M.B.A.
Headquarters
Waltham, MA
Employees
7
IPO year
2020

Financial highlights

Full financials

Damora Therapeutics reported a net loss of $209.8 million, compared with a loss of $21.4 million a year earlier. Diluted earnings per share came in at $3.98.

Damora Therapeutics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue—————
Growth—————
Net income$-209.84M$-21.44M$-38.35M$-61.62M$-51.75M
EPS (diluted)$3.98$-18.53$-36.08$-2.43$-2.05

Analyst forecast

Forecast

Consensus (10 analysts)

strong_buy

Avg. price target

$46.78+101.46%

  • Strong buy 1
  • Buy 9
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $40.00High $59.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 5, 2026
EPS actual vs est.
$-0.40 vs $-0.52
Surprise
+23.08%

DMRA news

All DMRA news

Damora Therapeutics peers

Health Care sector
DMRA peer companies
CompanyPrice% ChgMarket capCompare
KLRAKailera Therapeutics Inc.11.02-4.84%$1.43Bvs DMRA
SRPTSarepta Therapeutics Inc.13.33-5.93%$1.43Bvs DMRA
ADRXADARx Pharmaceuticals Inc.12.79-9.68%$1.42Bvs DMRA
NRIXNurix Therapeutics Inc.12.85-5.55%$1.40Bvs DMRA
TYRATyra Biosciences Inc.20.12+1.98%$1.39Bvs DMRA
ANABAnaptysBio Inc.46.63-1.62%$1.39Bvs DMRA
RAPPRapport Therapeutics Inc.23.16-1.82%$1.37Bvs DMRA
PGENPrecigen Inc.4.21+1.20%$1.51Bvs DMRA

Indexes, lists and sector

Damora Therapeutics stock FAQ

What is Damora Therapeutics's stock price today?

DMRA last traded at $23.22 as of Nov 20, 4:00 PM EST, down 4.44% on the day. Prices are delayed at least 15 minutes.

Does Damora Therapeutics pay a dividend?

No. Damora Therapeutics does not currently pay a regular cash dividend.

What is DMRA's P/E ratio?

DMRA trades at a trailing P/E ratio of 13.58, compared with a median of 7.2 for its closest peers.

Who is Damora Therapeutics's CEO?

Ms. Jennifer A. Jarrett M.B.A. is the chief executive officer of Damora Therapeutics Inc., which has about 7 employees.

Has DMRA ever split its stock?

Yes. The most recent DMRA stock split was a 1-for-25 split on Aug 30, 2024.

What is the DMRA 52-week high?

The 52-week high for DMRA is $38.33 and the 52-week low is $15.76. The stock is currently 39.4% below its high.

Compare DMRA